
Zynex Inc (ZYXI) Stock Forecast & Price Target
Zynex Inc (ZYXI) Analyst Ratings
Bulls say
Zynex Inc has demonstrated strong financial performance, evidenced by a 16% year-over-year growth in orders for fiscal year 2024, which reflects a robust demand for its electrotherapy and pain management devices. The company aims to enhance revenue generation by increasing sales per representative to $1 million, positioning itself for future growth. Additionally, Zynex's commitment to reducing reliance on opioids through advanced, non-opioid therapies, along with substantial cost reductions projected to save approximately $35 million annually, underscores its potential for improved profitability and market influence.
Bears say
Zynex Inc. has demonstrated a concerning financial outlook, highlighted by a projected 37% year-over-year decline in Q1 sales, anticipated to reach "at least $30 million." The company reported a Q4 revenue of $46 million, which represents a 3% decline compared to the previous year and fell short of internal projections. Additionally, Zynex is facing significant challenges, including potential regulatory hurdles and increased competition in the pain management sector, leading to a reevaluation of future sales expectations, now estimated to drop by 28% to $140 million in 2025.
This aggregate rating is based on analysts' research of Zynex Inc and is not a guaranteed prediction by Public.com or investment advice.
Zynex Inc (ZYXI) Analyst Forecast & Price Prediction
Start investing in Zynex Inc (ZYXI)
Order type
Buy in
Order amount
Est. shares
0 shares